Ainos (NASDAQ:AIMD) Stock Price Up 1.4% – Here’s Why

Ainos, Inc. (NASDAQ:AIMD) traded up 1.4% during mid-day trading on Thursday . The stock traded as high as $1.8928 and last traded at $1.8760. 11,109 shares traded hands during mid-day trading, a decline of 35% from the average session volume of 17,124 shares. The stock had previously closed at $1.85.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Ainos in a research note on Monday, December 29th. One investment analyst has rated the stock with a Sell rating, According to MarketBeat, the stock has a consensus rating of “Sell”.

Ainos Stock Up 1.4%

The stock has a market capitalization of $9.02 million, a price-to-earnings ratio of -0.47 and a beta of 2.45. The business has a 50-day moving average of $2.01 and a 200-day moving average of $2.89. The company has a debt-to-equity ratio of 1.10, a quick ratio of 2.67 and a current ratio of 2.96.

Ainos (NASDAQ:AIMD) last posted its earnings results on Thursday, November 13th. The company reported ($0.64) EPS for the quarter. The business had revenue of $0.00 million for the quarter.

Institutional Investors Weigh In On Ainos

A hedge fund recently bought a new stake in Ainos stock. Two Sigma Investments LP bought a new position in shares of Ainos, Inc. (NASDAQ:AIMD) during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor bought 23,008 shares of the company’s stock, valued at approximately $80,000. Two Sigma Investments LP owned approximately 0.48% of Ainos as of its most recent SEC filing.

Ainos Company Profile

Ainos, Inc (NASDAQ: AIMD) is a clinical‐stage biopharmaceutical company dedicated to developing inhalation therapies for patients with chronic pulmonary disorders. The company’s proprietary platform centers on a dry powder inhalation technology designed to deliver therapeutic agents directly to the lungs, potentially improving drug distribution and reducing systemic side effects compared to traditional oral or intravenous formulations.

The lead product candidate, AI‐401, is an inhaled formulation of ibuprofen in a dry powder format.